Abstract 89P
Background
Cold atmospheric plasma (CAP) has been studied for cancer treatment. One of its forms, CAP activated liquids (CAPAL), may be an alternative to intravesical agents to treat bladder cancer (BC). The surgical bipolar resectoscope, when in use, is a source of thermal plasma (TP), which exerts effects on the surrounding sodium chloride solution for irrigation (NaCl 0.9%), transforming it into a TP activated liquid (TPAL), which is produced in very close contact with the bladder wall. To accelerate a possible introduction of plasma-activated liquid in the treatment of BC, we decided to compare the properties and biological effects of CAPAL and TPAL.
Methods
An electronic device was designed by our group to create CAP. TP was produced by a resectoscope. NaCl 0.9% was exposed to CAP or TP during short periods of time (30, 60, 120, 180 seconds) creating CAPAL or TPAL. The reactive oxygen and nitrogen species (RONS) activity was evaluated using the OxiSelect™ RONS Assay Kit in each activated liquid. BC cell lines, TCCSUP (grade IV) and HT-1376 (grade III), were incubated with CAPAL or TPAL. Metabolic activity was evaluated by MTT assay and protein content by SRB assay, 24h post-incubation.
Results
In comparison to non irradiated NaCl 0.9%, both CAPAL and TPAL, in all exposure times resulted in a significant rise in the activity of RONS. Regarding the biological activity of the activated liquids in the BC cell lines, both CAPAL and TPAL induced a decrease in cell metabolic activity and protein content in an exposure-time dependent manner. CAPAL induced a higher antitumor effect on the high-grade cell line (TCCSUP), while TPAL had a similar effect on both cell lines. Comparing the two activated liquids, CAPAL required longer exposure times to achieve the same effects observed with TPAL at lower exposure times.
Conclusions
This study shows that PAL can be a therapeutic agent for BC. Both TPAL and CAPAL showed similar biologics in BC cells. Currently, in clinical practice, TPAL is already in close contact with the bladder wall during surgery, however only briefly and diluted by irrigation. This work intends to get one step closer to demonstrate that CAPAL can be a safe and effective BC treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Foundation For Science And Technology (FCT), Portugal, through the Strategic Projects, UIDB/04539/2020, UIDP/04539/2020, and by COMPETE-FEDER, reference number POCI-01-0145-FEDER-007440. Scholarship grants from FCT and European Social Funding to E.P. (2021.05543. BD).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
56P - SLC34A2-ROS1 L2026M+G2032R confers resistance to ROS1 tyrosine kinase inhibitors in Ba/F3 cells through a reduced ATP binding pocket volume
Presenter: Christa Dijkhuizen
Session: Poster session 09
57P - Metastasis organotropism: Unveiling associated proteins using network biology
Presenter: Margarida Carrolo
Session: Poster session 09
59P - Correlation of tumor microenvironment signature in advanced stage non-small cell lung cancer with EGFR mutation who received EGFR-TKIs
Presenter: Chaiyapong Ngamchokwathana
Session: Poster session 09
60P - Establishment and characterization of a novel lung adenocarcinoma cell line HX-JCJ harboring MET ex14 skipping mutation
Presenter: Xuejin Ou
Session: Poster session 09
61P - Next generation sequencing and its clinical utility in advanced cancer: Single institute experience from low-middle income country
Presenter: Amit Badola
Session: Poster session 09
62P - Prebiotics modulate gut microbiota-mediated T cell immunity to enhance sintilimab inhibition of lung cancer
Presenter: QIN YAN
Session: Poster session 09
63P - Addition of human chorionic gonadotropin to the current standard mobilization approach with granulocyte-colony stimulating factor increases overall survival in a murine model of peripheral blood stem cell transplantation: Are we far enough for therapy?
Presenter: Andrei Cismaru
Session: Poster session 09
64P - Developing novel therapeutics for bladder cancer leveraging drosophila models
Presenter: Takuya Moriguchi
Session: Poster session 09
65P - Ionizing radiation induces vascular smooth muscle cell senescence through activating NF-κB-CTCF-p16 pathway
Presenter: xuefeng zheng
Session: Poster session 09
66P - Exploring the radiobiology and dosimetry of targeted alpha therapy as a tool to optimize its clinical application: A preclinical study
Presenter: Maria Filomena Botelho
Session: Poster session 09